Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 6/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 6/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 6/20 | 0.51 |
| ▸ | ACSS2 | Q9NR19 | 13/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524938 | 1.00 | TPSAB1 (0.51) | TPSAB1TPSD1TPSG1ACSS2PIN1 | |
| SCHEMBL2526178 | 0.82 | PIN1 (0.41) | ACSS2PIN1 | |
| SCHEMBL2526173 | 0.82 | PIN1 (0.41) | ACSS2PIN1 | |
| SCHEMBL2528847 | 0.73 | PIN1 (0.39) | TPSAB1TPSD1TPSG1ACSS2PIN1 | |
| SCHEMBL2528844 | 0.73 | PIN1 (0.39) | TPSAB1TPSD1TPSG1ACSS2PIN1 | |
| SCHEMBL7489855 | 0.71 | PIN1 (0.46) | ACSS2PIN1 | |
| Hydrochloric Acid SCHEMBL7478353 | 0.71 | PIN1 (0.45) | ACSS2PIN1 | |
| SCHEMBL4555853 | 0.70 | F9 (0.31) | — | |
| SCHEMBL7478923 | 0.69 | TPSAB1 (0.39) | TPSAB1TPSD1TPSG1ACSS2PIN1 | |
| SCHEMBL7482199 | 0.69 | PIN1 (0.38) | TPSAB1TPSD1TPSG1ACSS2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | claimed |
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | TPSAB1 1978/4885TPSD1 555/4885TPSG1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.